Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Assets (2020 - 2025)

Historic Assets for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to $534.6 million.

  • Tarsus Pharmaceuticals' Assets rose 4205.71% to $534.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $534.6 million, marking a year-over-year increase of 4205.71%. This contributed to the annual value of $377.0 million for FY2024, which is 4199.77% up from last year.
  • As of Q3 2025, Tarsus Pharmaceuticals' Assets stood at $534.6 million, which was up 4205.71% from $495.0 million recorded in Q2 2025.
  • Tarsus Pharmaceuticals' Assets' 5-year high stood at $534.6 million during Q3 2025, with a 5-year trough of $178.9 million in Q4 2021.
  • Over the past 5 years, Tarsus Pharmaceuticals' median Assets value was $252.8 million (recorded in 2022), while the average stood at $295.2 million.
  • Per our database at Business Quant, Tarsus Pharmaceuticals' Assets surged by 10655.42% in 2021 and then crashed by 2527.45% in 2023.
  • Quarter analysis of 5 years shows Tarsus Pharmaceuticals' Assets stood at $178.9 million in 2021, then increased by 27.36% to $227.9 million in 2022, then grew by 16.51% to $265.5 million in 2023, then skyrocketed by 42.0% to $377.0 million in 2024, then soared by 41.8% to $534.6 million in 2025.
  • Its Assets stands at $534.6 million for Q3 2025, versus $495.0 million for Q2 2025 and $500.8 million for Q1 2025.